ReviewiScience2026
Optical mapping: pioneering the frontier of preclinical antiarrhythmic drug evaluation.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optical mapping has emerged as a unique technique in cardiac electrophysiology since its emergence in the 1970s. By acquiring high spatiotemporal resolution optical datasets using fluorescent dyes, this technique propels the progress of cardiac electrophysiology and the development of antiarrhythmic drug evaluation. This review outlines its application in drug evaluation, including the fundamental principles, major advantages, multiple electrophysiological parameters, and combination with other techniques for predicting proarrhythmic risk and identification of antiarrhythmic drugs. An overview of the drugs tested via the optical mapping method is presented, showcasing its extensive practical utility. This review provides a comprehensive framework for the analysis of arrhythmia mechanisms and drug development using optical mapping. Finally, its limitations and prospects of optical mapping in deciphering the arrhythmogenic mechanism and evaluating antiarrhythmic drugs are discussed, providing references for promoting its clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.